{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-022068","form_type":"8-K","ticker":"CRNX","cik":"0001658247","company_name":"Crinetics Pharmaceuticals, Inc.","filed_at":"2024-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.003806+00:00","generated_at":"2026-06-05T08:59:36.208157+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Crinetics reports Q4 net loss of $60.1M; announces $350M private placement; paltusotine NDA on track for 2H 2024","bullets":["Net loss for Q4 2023 was $60.1M vs $45.0M in Q4 2022; full-year net loss $214.5M vs $163.9M in 2022.","Cash, equivalents, and investments totaled $558.6M as of Dec 31, 2023; $350M private placement extends runway into 2028.","Phase 3 PATHFNDR-2 topline results for paltusotine in acromegaly expected March 2024; NDA submission planned 2H 2024.","Phase 2 paltusotine in carcinoid syndrome full topline results expected 1H 2024; initial data from 27 patients reported Dec 2023.","R&D expenses rose to $168.5M for FY2023 from $130.2M in FY2022, driven by higher personnel and outside services costs."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-022068","json":"https://secwatch.observer/filing/0000950170-24-022068.json","markdown":"https://secwatch.observer/filing/0000950170-24-022068.md","text":"https://secwatch.observer/filing/0000950170-24-022068.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1658247/000095017024022068/0000950170-24-022068-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1658247/000095017024022068/crnx-20240228.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T08:59:36.208157+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"49d288d49ca61d785baf00889bd4dcadee91be45","claim":"Crinetics Pharmaceuticals, Inc. reported the fourth quarter and full year ended December 31, 2023 results: revenue $4.0 million, net income net loss of $214.5 million.","evidence_excerpt":"ended December 31, 2022 and $1.0 million for the year ended December 31, 2022. This loss was derived from the company’s investment in Radionetics Oncology, Inc. • Revenues were $4.0 million for the full year ended December 31, 2023, compared to $4.7 million for the same period in 2022. There were no revenues for the three months ended December 31, 2023, compared to","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1658247/000095017024022068/0000950170-24-022068-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2023"},{"label":"Revenue","value":"$4.0 million"},{"label":"Net income","value":"net loss of $214.5 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}